You are here

Topical Ointment for OA Knee Pain Flunks Mid-Stage Trial

Sodium channel blocker is no better than placebo

Disappointing results have been reported from a double-blind, placebo-controlled, phase IIb study designed to evaluate the safety and efficacy of topically applied TV-45070 (4% and 8% w/w ointment, Teva Pharmaceutical Industries/ Xenon Pharmaceuticals) in patients with chronic pain due to osteoarthritis (OA) of the knee.

TV-45070 is a small-molecule inhibitor of the Nav1.7 sodium channel and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system.

In this study, TV-45070 4% and 8% did not demonstrate a statistically significant difference from placebo in efficacy endpoints of reductions in pain due to OA.

TV-45070 did have a favorable safety and tolerability profile, with no drug-related serious adverse events. The most common adverse events were application-site skin reactions, which were mostly mild. There were no cardiac or CNS safety issues.

Applied topically, TV-45070 acts locally to inhibit Nav1.7 in the skin and underlying tissue, mitigating systemic absorption and the potential risks of adverse effects that accompany systemic drug metabolism. A phase IIb trial of TV-45070 in patients with post-herpetic neuralgia is under way, with results expected in the second half of 2016.

The phase IIb study of TV-45070 in OA patients was a randomized, double-blind, placebo-controlled trial conducted at approximately 40 clinical sites in the US. A total of 389 patients were randomly assigned to receive TV-45070 4% administered twice per day; TV-45070 8% administered twice per day; or a placebo comparator (a matched ointment without TV-45070) administered twice per day. The patients were eligible to participate in the trial if they were 40 to 85 years of age, had primary OA in a single knee (the target knee), met pre-specified visual analog scale (VAS) pain scores, and were otherwise medically healthy.

The study’s primary endpoint was the efficacy of 4 weeks of topical administration of TV-45070 (4% and 8% ointment) compared with placebo for the relief of symptoms of primary OA of the target knee, as assessed by the change from baseline to the last 5 days of treatment in the average evening pain score upon walking on a flat surface, using question 1 of the Western Ontario and McMasters Universities Arthritis Index (WOMAC) on a 0- to 100-mm visual analog scale. Efficacy endpoints were analyzed in all patients who received at least one dose of study drug and at least one post-baseline efficacy assessment. Key secondary objectives of the trial included changes in the WOMAC pain subscale scores, responder rates, and patient-reported outcome assessments.

Source: Xenon Pharmaceuticals; July 1, 2015.

 

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential